Septerna, Inc. Contract Liability (Deferred Revenue)
Septerna, Inc. (SEPN) had Contract Liability (Deferred Revenue) of $60.35 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-08-10
- 2026-06-30: Contract with Customer, Liability, Current $60.35M.
- 2026-03-31: Contract with Customer, Liability, Current $59.76M.
- 2025-12-31: Contract with Customer, Liability, Current $62.27M.
- 2025-09-30: Contract with Customer, Liability, Current $61.60M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $60.35M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $59.76M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $62.27M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $61.60M 10-Q · filed 2025-11-10 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |